<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:49:16 -0700</creation_date>
  <update_date>2013-05-27 11:41:22 -0600</update_date>
  <accession>HMDBP00181</accession>
  <secondary_accessions>
    <accession>5413</accession>
    <accession>HMDBP05346</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>XD</synonym>
    <synonym>XO</synonym>
    <synonym>Xanthine dehydrogenase</synonym>
    <synonym>Xanthine oxidase</synonym>
    <synonym>Xanthine oxidoreductase</synonym>
  </synonyms>
  <gene_name>XDH</gene_name>
  <general_function>Involved in oxidoreductase activity</general_function>
  <specific_function>Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro).
</specific_function>
  <pathways>
    <pathway>
      <name>Purine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00230</kegg_map_id>
    </pathway>
    <pathway>
      <name>Caffeine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00232</kegg_map_id>
    </pathway>
    <pathway>
      <name>Drug metabolism - other enzymes</name>
      <smpdb_id/>
      <kegg_map_id>map00983</kegg_map_id>
    </pathway>
    <pathway>
      <name>Peroxisome</name>
      <smpdb_id/>
      <kegg_map_id>map04146</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB01860</accession>
      <name>Paraxanthine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01991</accession>
      <name>7-Methylxanthine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03099</accession>
      <name>1-Methyluric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11103</accession>
      <name>1,7-Dimethyluric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11107</accession>
      <name>7-Methyluric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB10738</accession>
      <name>1-Methylxanthine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00157</accession>
      <name>Hypoxanthine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00292</accession>
      <name>Xanthine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00289</accession>
      <name>Uric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01248</accession>
      <name>FAD</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00902</accession>
      <name>NAD</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01487</accession>
      <name>NADH</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00034</accession>
      <name>Adenine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01892</accession>
      <name>Menadione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00692</accession>
      <name>Fe2+</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01302</accession>
      <name>Molybdenum</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01377</accession>
      <name>Oxygen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02206</accession>
      <name>Molybdopterin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03125</accession>
      <name>Hydrogen peroxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01256</accession>
      <name>Spermine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01982</accession>
      <name>3,7-Dimethyluric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02825</accession>
      <name>Theobromine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01978</accession>
      <name>5-Hydroxypyrazinamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14480</accession>
      <name>Nitrofurazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14483</accession>
      <name>Pyrazinamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14581</accession>
      <name>Allopurinol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14656</accession>
      <name>Cisplatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00062</accession>
      <name>L-Carnitine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14832</accession>
      <name>Daunorubicin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14884</accession>
      <name>Deferoxamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14969</accession>
      <name>Trifluoperazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14994</accession>
      <name>Chlorphenesin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15093</accession>
      <name>Carboplatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15128</accession>
      <name>Azathioprine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15167</accession>
      <name>Mercaptopurine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13946</accession>
      <name>8-Hydroxycarvedilol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15299</accession>
      <name>Procarbazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15408</accession>
      <name>Bismuth Subsalicylate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00195</accession>
      <name>Inosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB59597</accession>
      <name>Hydrogen Ion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB60417</accession>
      <name>6-Thiourate</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>molybdenum ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on ch or ch2 groups, oxygen as acceptor</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>xanthine oxidase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on ch or ch2 groups</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on ch or ch2 groups, nad or nadp as acceptor</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>xanthine dehydrogenase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal cluster binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>iron-sulfur cluster binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>purine nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>fad or fadh2 binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>iron ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>electron carrier activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>extracellular region</description>
      <go_id>GO:0005576</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>peroxisome</description>
      <go_id>GO:0005777</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>2 iron, 2 sulfur cluster binding</description>
      <go_id>GO:0051537</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>electron carrier activity</description>
      <go_id>GO:0009055</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>flavin adenine dinucleotide binding</description>
      <go_id>GO:0050660</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>iron ion binding</description>
      <go_id>GO:0005506</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>molybdopterin cofactor binding</description>
      <go_id>GO:0043546</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>UDP-N-acetylmuramate dehydrogenase activity</description>
      <go_id>GO:0008762</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>xanthine dehydrogenase activity</description>
      <go_id>GO:0004854</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>xanthine oxidase activity</description>
      <go_id>GO:0004855</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>activation of cysteine-type endopeptidase activity involved in apoptotic process</description>
      <go_id>GO:0006919</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>lactation</description>
      <go_id>GO:0007595</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of endothelial cell differentiation</description>
      <go_id>GO:0045602</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of endothelial cell proliferation</description>
      <go_id>GO:0001937</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of gene expression</description>
      <go_id>GO:0010629</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of protein kinase B signaling cascade</description>
      <go_id>GO:0051898</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of protein phosphorylation</description>
      <go_id>GO:0001933</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of vascular endothelial growth factor signaling pathway</description>
      <go_id>GO:1900747</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of vasculogenesis</description>
      <go_id>GO:2001213</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of p38MAPK cascade</description>
      <go_id>GO:1900745</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of reactive oxygen species metabolic process</description>
      <go_id>GO:2000379</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>purine nucleotide catabolic process</description>
      <go_id>GO:0006195</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>xanthine catabolic process</description>
      <go_id>GO:0009115</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cytoplasm</subcellular_location>
    <subcellular_location>Peroxisome</subcellular_location>
    <subcellular_location>Secreted</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>2</chromosome_location>
    <locus>2p23.1</locus>
    <gene_sequence>&gt;4002 bp
ATGACAGCAGACAAATTGGTTTTCTTTGTGAATGGCAGAAAGGTGGTGGAGAAAAATGCA
GATCCAGAGACAACCCTTTTGGCCTACCTGAGAAGAAAGTTGGGGCTGAGTGGAACCAAG
CTCGGCTGTGGAGAGGGGGGCTGCGGGGCTTGCACAGTGATGCTCTCCAAGTATGATCGT
CTGCAGAACAAGATCGTCCACTTTTCTGCCAATGCCTGCCTGGCCCCCATCTGCTCCTTG
CACCATGTTGCAGTGACAACTGTGGAAGGAATAGGAAGCACCAAGACGAGGCTGCATCCT
GTGCAGGAGAGAATTGCCAAAAGCCACGGCTCCCAGTGCGGGTTCTGCACCCCTGGCATC
GTCATGAGTATGTACACACTGCTCCGGAATCAGCCCGAGCCCACCATGGAGGAGATTGAG
AATGCCTTCCAAGGAAATCTGTGCCGCTGCACAGGCTACAGACCCATCCTCCAGGGCTTC
CGGACCTTTGCCAGGGATGGTGGATGCTGTGGAGGAGATGGGAATAATCCAAATTGCTGC
ATGAACCAGAAGAAAGACCACTCAGTCAGCCTCTCGCCATCTTTATTCAAACCAGAGGAG
TTCACGCCCCTGGATCCAACCCAGGAGCCCATTTTTCCCCCAGAGTTGCTGAGGCTGAAA
GACACTCCTCGGAAGCAGCTGCGATTTGAAGGGGAGCGTGTGACGTGGATACAGGCCTCA
ACCCTCAAGGAGCTGCTGGACCTCAAGGCTCAGCACCCTGACGCCAAGCTGGTCGTGGGG
AACACGGAGATTGGCATTGAGATGAAGTTCAAGAATATGCTGTTTCCTATGATTGTCTGC
CCAGCCTGGATCCCTGAGCTGAATTCGGTAGAACATGGACCCGACGGTATCTCCTTTGGA
GCTGCTTGCCCCCTGAGCATTGTGGAAAAAACCCTGGTGGATGCTGTTGCTAAGCTTCCT
GCCCAAAAGACAGAGGTGTTCAGAGGGGTCCTGGAGCAGCTGCGCTGGTTTGCTGGGAAG
CAAGTCAAGTCTGTGGCGTCCGTTGGAGGGAACATCATCACTGCCAGCCCCATCTCCGAC
CTCAACCCCGTGTTCATGGCCAGTGGGGCCAAGCTGACACTTGTGTCCAGAGGCACCAGG
AGAACTGTCCAGATGGACCACACCTTCTTCCCTGGCTACAGAAAGACCCTGCTGAGCCCG
GAGGAGATACTGCTCTCCATAGAGATCCCCTACAGCAGGGAGGGGGAGTATTTCTCAGCA
TTCAAGCAGGCCTCCCGGAGAGAAGATGACATTGCCAAGGTAACCAGTGGCATGAGAGTT
TTATTCAAGCCAGGAACCACAGAGGTACAGGAGCTGGCCCTTTGCTATGGTGGAATGGCC
AACAGAACCATCTCAGCCCTCAAGACCACTCAGAGGCAGCTTTCCAAGCTCTGGAAGGAG
GAGCTGCTGCAGGACGTGTGTGCAGGACTGGCAGAGGAGCTGCATCTGCCTCCCGATGCC
CCTGGTGGCATGGTGGACTTCCGGTGCACCCTCACCCTCAGCTTCTTCTTCAAGTTCTAC
CTGACAGTCCTTCAGAAGCTGGGCCAAGAGAACCTGGAAGACAAGTGTGGTAAACTGGAC
CCCACTTTCGCCAGTGCAACTTTACTGTTTCAGAAAGACCCCCCAGCCGATGTCCAGCTC
TTCCAAGAGGTGCCCAAGGGTCAGTCTGAGGAGGACATGGTGGGCCGGCCCCTGCCCCAC
CTGGCAGCGGACATGCAGGCCTCTGGTGAGGCCGTGTACTGTGACGACATTCCTCGCTAC
GAGAATGAGCTGTCTCTCCGGCTGGTCACCAGCACCCGGGCCCACGCCAAGATCAAGTCC
ATAGATACATCAGAAGCTAAGAAGGTTCCAGGGTTTGTTTGTTTCATTTCCGCTGATGAT
GTTCCTGGGAGTAACATAACTGGAATTTGTAATGATGAGACAGTCTTTGCGAAGGATAAG
GTTACTTGTGTTGGGCATATCATTGGTGCTGTGGTTGCTGACACCCCGGAACACACACAG
AGAGCTGCCCAAGGGGTGAAAATCACCTATGAAGAACTACCAGCCATTATCACAATTGAG
GATGCTATAAAGAACAACTCCTTTTATGGACCTGAGCTGAAGATCGAGAAAGGGGACCTA
AAGAAGGGGTTTTCCGAAGCAGATAATGTTGTGTCAGGGGAGATATACATCGGTGGCCAA
GAGCACTTCTACCTGGAGACTCACTGCACCATTGCTGTTCCAAAAGGCGAGGCAGGGGAG
ATGGAGCTCTTTGTGTCTACACAGAACACCATGAAGACCCAGAGCTTTGTTGCAAAAATG
TTGGGGGTTCCAGCAAACCGGATTGTGGTTCGAGTGAAGAGAATGGGAGGAGGCTTTGGA
GGCAAGGAGACCCGGAGCACTGTGGTGTCCACGGCAGTGGCCCTGGCTGCATATAAGACC
GGCCGCCCTGTGCGATGCATGCTGGACCGTGATGAGGACATGCTGATAACTGGTGGCAGA
CATCCCTTCCTGGCCAGATACAAGGTTGGCTTCATGAAGACTGGGACAGTTGTGGCTCTT
GAGGTGGACCACTTCAGCAATGTGGGGAACACCCAGGATCTCTCTCAGAGTATTATGGAA
CGAGCTTTATTCCACATGGACAACTGCTATAAAATCCCCAACATCCGGGGCACTGGGCGG
CTGTGCAAAACCAACCTTCCCTCCAACACGGCCTTCCGGGGCTTTGGGGGGCCCCAGGGG
ATGCTCATTGCCGAGTGCTGGATGAGTGAAGTTGCAGTGACCTGTGGGATGCCTGCAGAG
GAGGTGCGGAGAAAAAACCTGTACAAAGAAGGGGACCTGACACACTTCAACCAGAAGCTT
GAGGGTTTCACCTTGCCCAGATGCTGGGAAGAATGCCTAGCAAGCTCTCAGTATCATGCT
CGGAAGAGTGAGGTTGACAAGTTCAACAAGGAGAATTGTTGGAAAAAGAGAGGATTGTGC
ATAATTCCCACCAAGTTTGGAATAAGCTTCACAGTTCCTTTTCTGAATCAGGCAGGAGCC
CTACTTCATGTGTACACAGATGGCTCTGTGCTGCTGACCCACGGGGGGACTGAGATGGGC
CAAGGCCTTCATACCAAAATGGTCCAGGTGGCCAGTAGAGCTCTGAAAATCCCCACCTCT
AAGATTTATATCAGCGAGACAAGCACTAACACTGTGCCCAACACCTCTCCCACGGCTGCC
TCTGTCAGCGCTGACCTCAATGGACAGGCCGTCTATGCGGCTTGTCAGACCATCTTGAAA
AGGCTGGAACCCTACAAGAAGAAGAATCCCAGTGGCTCCTGGGAAGACTGGGTCACAGCT
GCCTACATGGACACAGTGAGCTTGTCTGCCACTGGGTTTTATAGAACACCCAATCTGGGC
TACAGCTTTGAGACTAACTCAGGGAACCCCTTCCACTACTTCAGCTATGGGGTGGCTTGC
TCTGAAGTAGAAATCGACTGCCTAACAGGAGATCATAAGAACCTCCGCACAGATATTGTC
ATGGATGTTGGCTCCAGTCTAAACCCTGCCATTGATATTGGACAGGTGGAAGGGGCATTT
GTCCAGGGCCTTGGCCTCTTCACCCTAGAGGAGCTACACTATTCCCCCGAGGGGAGCCTG
CACACCCGTGGCCCTAGCACCTACAAGATCCCGGCATTTGGCAGCATCCCCATTGAGTTC
AGGGTGTCCCTGCTCCGCGACTGCCCCAACAAGAAGGCCATCTATGCATCGAAGGCTGTT
GGAGAGCCGCCCCTCTTCCTGGCTGCTTCTATCTTCTTTGCCATCAAAGATGCCATCCGT
GCAGCTCGAGCTCAGCACACAGGTAATAACGTGAAGGAACTCTTCCGGCTAGACAGCCCT
GCCACCCCGGAGAAGATCCGCAATGCCTGCGTGGACAAGTTCACCACCCTGTGTGTCACT
GGTGTCCCAGAAAACTGCAAACCCTGGTCTGTGAGGGTCTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>1333</residue_number>
    <molecular_weight>146422.99</molecular_weight>
    <theoretical_pi>7.663</theoretical_pi>
    <pfams>
      <pfam>
        <name>Ald_Xan_dh_C</name>
        <pfam_id>PF01315</pfam_id>
      </pfam>
      <pfam>
        <name>Ald_Xan_dh_C2</name>
        <pfam_id>PF02738</pfam_id>
      </pfam>
      <pfam>
        <name>CO_deh_flav_C</name>
        <pfam_id>PF03450</pfam_id>
      </pfam>
      <pfam>
        <name>FAD_binding_5</name>
        <pfam_id>PF00941</pfam_id>
      </pfam>
      <pfam>
        <name>Fer2</name>
        <pfam_id>PF00111</pfam_id>
      </pfam>
      <pfam>
        <name>Fer2_2</name>
        <pfam_id>PF01799</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Xanthine dehydrogenase/oxidase
MTADKLVFFVNGRKVVEKNADPETTLLAYLRRKLGLSGTKLGCGEGGCGACTVMLSKYDR
LQNKIVHFSANACLAPICSLHHVAVTTVEGIGSTKTRLHPVQERIAKSHGSQCGFCTPGI
VMSMYTLLRNQPEPTMEEIENAFQGNLCRCTGYRPILQGFRTFARDGGCCGGDGNNPNCC
MNQKKDHSVSLSPSLFKPEEFTPLDPTQEPIFPPELLRLKDTPRKQLRFEGERVTWIQAS
TLKELLDLKAQHPDAKLVVGNTEIGIEMKFKNMLFPMIVCPAWIPELNSVEHGPDGISFG
AACPLSIVEKTLVDAVAKLPAQKTEVFRGVLEQLRWFAGKQVKSVASVGGNIITASPISD
LNPVFMASGAKLTLVSRGTRRTVQMDHTFFPGYRKTLLSPEEILLSIEIPYSREGEYFSA
FKQASRREDDIAKVTSGMRVLFKPGTTEVQELALCYGGMANRTISALKTTQRQLSKLWKE
ELLQDVCAGLAEELHLPPDAPGGMVDFRCTLTLSFFFKFYLTVLQKLGQENLEDKCGKLD
PTFASATLLFQKDPPADVQLFQEVPKGQSEEDMVGRPLPHLAADMQASGEAVYCDDIPRY
ENELSLRLVTSTRAHAKIKSIDTSEAKKVPGFVCFISADDVPGSNITGICNDETVFAKDK
VTCVGHIIGAVVADTPEHTQRAAQGVKITYEELPAIITIEDAIKNNSFYGPELKIEKGDL
KKGFSEADNVVSGEIYIGGQEHFYLETHCTIAVPKGEAGEMELFVSTQNTMKTQSFVAKM
LGVPANRIVVRVKRMGGGFGGKETRSTVVSTAVALAAYKTGRPVRCMLDRDEDMLITGGR
HPFLARYKVGFMKTGTVVALEVDHFSNVGNTQDLSQSIMERALFHMDNCYKIPNIRGTGR
LCKTNLPSNTAFRGFGGPQGMLIAECWMSEVAVTCGMPAEEVRRKNLYKEGDLTHFNQKL
EGFTLPRCWEECLASSQYHARKSEVDKFNKENCWKKRGLCIIPTKFGISFTVPFLNQAGA
LLHVYTDGSVLLTHGGTEMGQGLHTKMVQVASRALKIPTSKIYISETSTNTVPNTSPTAA
SVSADLNGQAVYAACQTILKRLEPYKKKNPSGSWEDWVTAAYMDTVSLSATGFYRTPNLG
YSFETNSGNPFHYFSYGVACSEVEIDCLTGDHKNLRTDIVMDVGSSLNPAIDIGQVEGAF
VQGLGLFTLEELHYSPEGSLHTRGPSTYKIPAFGSIPIEFRVSLLRDCPNKKAIYASKAV
GEPPLFLAASIFFAIKDAIRAARAQHTGNNVKELFRLDSPATPEKIRNACVDKFTTLCVT
GVPENCKPWSVRV</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P47989</uniprot_id>
  <uniprot_name>XDH_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>2CKJ</pdb_id>
    <pdb_id>2E1Q</pdb_id>
  </pdb_ids>
  <genbank_gene_id>D11456</genbank_gene_id>
  <genecard_id>XDH</genecard_id>
  <geneatlas_id>XDH</geneatlas_id>
  <hgnc_id>HGNC:12805</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Ichida K, Amaya Y, Noda K, Minoshima S, Hosoya T, Sakai O, Shimizu N, Nishino T: Cloning of the cDNA encoding human xanthine dehydrogenase (oxidase): structural analysis of the protein and chromosomal location of the gene. Gene. 1993 Nov 15;133(2):279-84.</reference_text>
      <pubmed_id>8224915</pubmed_id>
    </reference>
    <reference>
      <reference_text>Xu P, Huecksteadt TP, Harrison R, Hoidal JR: Molecular cloning, tissue expression of human xanthine dehydrogenase.  Biochem Biophys Res Commun. 1994 Mar 15;199(2):998-1004.</reference_text>
      <pubmed_id>8135849</pubmed_id>
    </reference>
    <reference>
      <reference_text>Xu P, Huecksteadt TP, Harrison R, Hoidal JR: Molecular cloning, tissue expression of human xanthine dehydrogenase.  Biochem Biophys Res Commun. 1995 Oct 4;215(1):429.</reference_text>
      <pubmed_id>7575623</pubmed_id>
    </reference>
    <reference>
      <reference_text>Saksela M, Raivio KO: Cloning and expression in vitro of human xanthine dehydrogenase/oxidase.  Biochem J. 1996 Apr 1;315 ( Pt 1):235-9.</reference_text>
      <pubmed_id>8670112</pubmed_id>
    </reference>
    <reference>
      <reference_text>Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006 Nov 3;127(3):635-48.</reference_text>
      <pubmed_id>17081983</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ichida K, Amaya Y, Kamatani N, Nishino T, Hosoya T, Sakai O: Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria. J Clin Invest. 1997 May 15;99(10):2391-7.</reference_text>
      <pubmed_id>9153281</pubmed_id>
    </reference>
    <reference>
      <reference_text>Levartovsky D, Lagziel A, Sperling O, Liberman U, Yaron M, Hosoya T, Ichida K, Peretz H: XDH gene mutation is the underlying cause of classical xanthinuria: a second report. Kidney Int. 2000 Jun;57(6):2215-20.</reference_text>
      <pubmed_id>10844591</pubmed_id>
    </reference>
    <reference>
      <reference_text>Picariello G, Ferranti P, Mamone G, Roepstorff P, Addeo F: Identification of N-linked glycoproteins in human milk by hydrophilic interaction liquid chromatography and mass spectrometry. Proteomics. 2008 Sep;8(18):3833-47.</reference_text>
      <pubmed_id>18780401</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yamaguchi Y, Matsumura T, Ichida K, Okamoto K, Nishino T: Human xanthine oxidase changes its substrate specificity to aldehyde oxidase type upon mutation of amino acid residues in the active site: roles of active site residues in binding and activation of purine substrate. J Biochem. 2007 Apr;141(4):513-24. Epub 2007 Feb 14.</reference_text>
      <pubmed_id>17301077</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sakamoto N, Yamamoto T, Moriwaki Y, Teranishi T, Toyoda M, Onishi Y, Kuroda S, Sakaguchi K, Fujisawa T, Maeda M, Hada T: Identification of a new point mutation in the human xanthine dehydrogenase gene responsible for a case of classical type I xanthinuria. Hum Genet. 2001 Apr;108(4):279-83.</reference_text>
      <pubmed_id>11379872</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gok F, Ichida K, Topaloglu R: Mutational analysis of the xanthine dehydrogenase gene in a Turkish family with autosomal recessive classical xanthinuria. Nephrol Dial Transplant. 2003 Nov;18(11):2278-83.</reference_text>
      <pubmed_id>14551354</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers.  Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.</reference_text>
      <pubmed_id>16959974</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Adenine</name>
        <accession>HMDB00034</accession>
      </metabolite>
      <reference>
        <reference_text>Bouzidi H, Lacour B, Daudon M: [2,8-dihydroxyadenine nephrolithiasis: from diagnosis to therapy]  Ann Biol Clin (Paris). 2007 Nov-Dec;65(6):585-92.</reference_text>
        <pubmed_id>18039602</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Menadione</name>
        <accession>HMDB01892</accession>
      </metabolite>
      <reference>
        <reference_text>Yee SB, Pritsos CA: Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase. Arch Biochem Biophys. 1997 Nov 15;347(2):235-41.</reference_text>
        <pubmed_id>9367530</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Spermine</name>
        <accession>HMDB01256</accession>
      </metabolite>
      <reference>
        <reference_text>Lovaas E, Carlin G: Spermine: an anti-oxidant and anti-inflammatory agent.  Free Radic Biol Med. 1991;11(5):455-61.</reference_text>
        <pubmed_id>1663062</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxypyrazinamide</name>
        <accession>HMDB01978</accession>
      </metabolite>
      <reference>
        <reference_text>Yamamoto T, Moriwaki Y, Takahashi S, Hada T, Higashino K: In vitro conversion of pyrazinamide into 5-hydroxypyrazinamide and that of pyrazinoic acid into 5-hydroxypyrazinoic acid by xanthine oxidase from human liver. Biochem Pharmacol. 1987 Oct 1;36(19):3317-8.</reference_text>
        <pubmed_id>3663245</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrofurazone</name>
        <accession>HMDB14480</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsumi K, Kitamura S, Yoshimura H: Reduction of nitrofuran derivatives by xanthine oxidase and microsomes. Isolation and identification of reduction products. Arch Biochem Biophys. 1976 Jul;175(1):131-7.</reference_text>
        <pubmed_id>952514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrofurazone</name>
        <accession>HMDB14480</accession>
      </metabolite>
      <reference>
        <reference_text>Kutcher WW, McCalla DR: Aerobic reduction of 5-nitro-2-furaldehyde semicarbazone by rat liver xanthine dehydrogenase. Biochem Pharmacol. 1984 Mar 1;33(5):799-805.</reference_text>
        <pubmed_id>6585203</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyrazinamide</name>
        <accession>HMDB14483</accession>
      </metabolite>
      <reference>
        <reference_text>Moriwaki Y, Yamamoto T, Nasako Y, Takahashi S, Suda M, Hiroishi K, Hada T, Higashino K: In vitro oxidation of pyrazinamide and allopurinol by rat liver aldehyde oxidase.  Biochem Pharmacol. 1993 Sep 14;46(6):975-81.</reference_text>
        <pubmed_id>8216357</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki I, Yamauchi T, Onuma M, Nozaki S: Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders? Drugs Today (Barc). 2009 May;45(5):363-78.</reference_text>
        <pubmed_id>19584965</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>Carro MD, Falkenstein E, Radke WJ, Klandorf H: Effects of allopurinol on uric acid concentrations, xanthine oxidoreductase activity and oxidative stress in broiler chickens. Comp Biochem Physiol C Toxicol Pharmacol. 2010 Jan;151(1):12-7. Epub 2009 Aug 3.</reference_text>
        <pubmed_id>19654053</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>George J, Struthers AD: Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 2009;5(1):265-72. Epub 2009 Apr 8.</reference_text>
        <pubmed_id>19436671</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>Higgins P, Dawson J, Walters M: The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease. Cardiovasc Psychiatry Neurol. 2009;2009:282059. Epub 2009 Nov 4.</reference_text>
        <pubmed_id>20029618</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>Dincer HE, Dincer AP, Levinson DJ: Asymptomatic hyperuricemia: to treat or not to treat.  Cleve Clin J Med. 2002 Aug;69(8):594, 597, 600-2 passim.</reference_text>
        <pubmed_id>12184468</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>Kelley WN, Wyngaarden JB: Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells. J Clin Invest. 1970 Mar;49(3):602-9.</reference_text>
        <pubmed_id>5415686</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>Okamoto K: [Inhibitors of xanthine oxidoreductase].  Nihon Rinsho. 2008 Apr;66(4):748-53.</reference_text>
        <pubmed_id>18409526</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>Taha MO, Simoes MJ, Noguerol EC, Mendonca FP, Pascoalick HM, Alves RA, Vivian ME, Morales FP, Campos AC, Magalhaes KG, Venerando PS, Tersariol IL, Monteiro HP, Oliveira-Junior IS, Jurkiewicz A, Caricati-Neto A: Effects of allopurinol on ischemia and reperfusion in rabbit livers.  Transplant Proc. 2009 Apr;41(3):820-3.</reference_text>
        <pubmed_id>19376361</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>Terkeltaub R: Update on gout: new therapeutic strategies and options.  Nat Rev Rheumatol. 2010 Jan;6(1):30-8.</reference_text>
        <pubmed_id>20046204</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>Pacher P, Nivorozhkin A, Szabo C: Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58(1):87-114.</reference_text>
        <pubmed_id>16507884</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allopurinol</name>
        <accession>HMDB14581</accession>
      </metabolite>
      <reference>
        <reference_text>Moriwaki Y, Yamamoto T, Nasako Y, Takahashi S, Suda M, Hiroishi K, Hada T, Higashino K: In vitro oxidation of pyrazinamide and allopurinol by rat liver aldehyde oxidase.  Biochem Pharmacol. 1993 Sep 14;46(6):975-81.</reference_text>
        <pubmed_id>8216357</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisplatin</name>
        <accession>HMDB14656</accession>
      </metabolite>
      <reference>
        <reference_text>Yilmaz HR, Sogut S, Ozyurt B, Ozugurlu F, Sahin S, Isik B, Uz E, Ozyurt H: The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: protective effect of caffeic acid phenethyl ester. Toxicol Ind Health. 2005 May;21(3-4):67-73.</reference_text>
        <pubmed_id>15986578</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisplatin</name>
        <accession>HMDB14656</accession>
      </metabolite>
      <reference>
        <reference_text>Cetin R, Devrim E, Kilicoglu B, Avci A, Candir O, Durak I: Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol. 2006 Jan-Feb;26(1):42-6.</reference_text>
        <pubmed_id>16158393</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisplatin</name>
        <accession>HMDB14656</accession>
      </metabolite>
      <reference>
        <reference_text>Erdogan S, Tosyali E, Duzguner V, Kucukgul A, Aslantas O, Celik S: Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26. Epub 2009 Oct 8.</reference_text>
        <pubmed_id>19818462</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L-Carnitine</name>
        <accession>HMDB00062</accession>
      </metabolite>
      <reference>
        <reference_text>Di Giacomo C, Latteri F, Fichera C, Sorrenti V, Campisi A, Castorina C, Russo A, Pinturo R, Vanella A: Effect of acetyl-L-carnitine on lipid peroxidation and xanthine oxidase activity in rat skeletal muscle. Neurochem Res. 1993 Nov;18(11):1157-62.</reference_text>
        <pubmed_id>8255367</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Yee SB, Pritsos CA: Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase. Arch Biochem Biophys. 1997 Nov 15;347(2):235-41.</reference_text>
        <pubmed_id>9367530</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Yee SB, Pritsos CA: Reductive activation of doxorubicin by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. Chem Biol Interact. 1997 May 2;104(2-3):87-101.</reference_text>
        <pubmed_id>9212777</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Deferoxamine</name>
        <accession>HMDB14884</accession>
      </metabolite>
      <reference>
        <reference_text>Rinaldo JE, Gorry M: Protection by deferoxamine from endothelial injury: a possible link with inhibition of intracellular xanthine oxidase. Am J Respir Cell Mol Biol. 1990 Dec;3(6):525-33.</reference_text>
        <pubmed_id>2252579</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoperazine</name>
        <accession>HMDB14969</accession>
      </metabolite>
      <reference>
        <reference_text>Hirata Y, Ishii K, Taguchi T, Suita S, Takeshige K: Conversion of xanthine dehydrogenase to xanthine oxidase during ischemia of the rat small intestine and the effect of trifluoperazine on the conversion. J Pediatr Surg. 1993 Apr;28(4):597-600.</reference_text>
        <pubmed_id>8483075</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoperazine</name>
        <accession>HMDB14969</accession>
      </metabolite>
      <reference>
        <reference_text>Greene EL, Paller MS: Calcium and free radicals in hypoxia/reoxygenation injury of renal epithelial cells. Am J Physiol. 1994 Jan;266(1 Pt 2):F13-20.</reference_text>
        <pubmed_id>8304479</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorphenesin</name>
        <accession>HMDB14994</accession>
      </metabolite>
      <reference>
        <reference_text>Springer RH, Dimmitt MK, Novinson T, O'Brien DE, Robins RK, Simon LN, Miller JP: Synthesis and enzymic activity of some novel xanthine oxidase inhibitors. 3-Substituted 5,7-dihydroxypyrazolo(1,5-alpha)pyrimidines. J Med Chem. 1976 Feb;19(2):291-6.</reference_text>
        <pubmed_id>2778</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carboplatin</name>
        <accession>HMDB15093</accession>
      </metabolite>
      <reference>
        <reference_text>Husai K, Jagannathan R, Hasan Z, Trammell GL, Rybak LP, Hazelrigg SR, Somani SM: Dose response of carboplatin-induced nephrotoxicity in rats.  Pharmacol Toxicol. 2002 Aug;91(2):83-9.</reference_text>
        <pubmed_id>12420797</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carboplatin</name>
        <accession>HMDB15093</accession>
      </metabolite>
      <reference>
        <reference_text>Husain K, Whitworth C, Rybak LP: Time response of carboplatin-induced nephrotoxicity in rats.  Pharmacol Res. 2004 Sep;50(3):291-300.</reference_text>
        <pubmed_id>15225673</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carboplatin</name>
        <accession>HMDB15093</accession>
      </metabolite>
      <reference>
        <reference_text>Husain K, Whitworth C, Somani SM, Rybak LP: Carboplatin-induced oxidative stress in rat cochlea.  Hear Res. 2001 Sep;159(1-2):14-22.</reference_text>
        <pubmed_id>11520631</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carboplatin</name>
        <accession>HMDB15093</accession>
      </metabolite>
      <reference>
        <reference_text>Husain K, Whitworth C, Hazelrigg S, Rybak L: Carboplatin-induced oxidative injury in rat inferior colliculus.  Int J Toxicol. 2003 Sep-Oct;22(5):335-42.</reference_text>
        <pubmed_id>14555405</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azathioprine</name>
        <accession>HMDB15128</accession>
      </metabolite>
      <reference>
        <reference_text>Dubinsky MC: Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004 Sep;2(9):731-43.</reference_text>
        <pubmed_id>15354273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mercaptopurine</name>
        <accession>HMDB15167</accession>
      </metabolite>
      <reference>
        <reference_text>Dubinsky MC: Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004 Sep;2(9):731-43.</reference_text>
        <pubmed_id>15354273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Yue TL, McKenna PJ, Gu JL, Cheng HY, Ruffolo RE Jr, Feuerstein GZ: Carvedilol, a new vasodilating beta adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc Res. 1994 Mar;28(3):400-6.</reference_text>
        <pubmed_id>7909721</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bismuth Subsalicylate</name>
        <accession>HMDB15408</accession>
      </metabolite>
      <reference>
        <reference_text>Lewis RW, Olivier G: In vitro oxidation of 6-MP and its metallo complexes by xanthine oxidase.  Res Commun Chem Pathol Pharmacol. 1977 Oct;18(2):377-80.</reference_text>
        <pubmed_id>918354</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Inosine</name>
        <accession>HMDB00195</accession>
      </metabolite>
      <reference>
        <reference_text>STIRPE F, DELLACORTE E: REGULATION OF XANTHINE DEHYDROGENASE IN CHICK LIVER. EFFECT OF STARVATION AND OF ADMINISTRATION OF PURINES AND PURINE NUCLEOSIDES. Biochem J. 1965 Feb;94:309-13.</reference_text>
        <pubmed_id>14348191</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
